ChemicalBook
Chinese Japanese Germany Korea

Lenalidomide

Antitumor Drug
Lenalidomide
Lenalidomide structure
CAS No.
191732-72-6
Chemical Name:
Lenalidomide
Synonyms
CC-5013;Revlimi;Revlimid;lenalidomide;To the amine;LenalidoMide-d5;Lenalidomide ,98%;LenalidoMide (CC-5013);SGT67 lila@tuskwei.com;LenalidoMide (RevliMid)
CBNumber:
CB3855432
Molecular Formula:
C13H13N3O3
Formula Weight:
259.26062
MOL File:
191732-72-6.mol

Lenalidomide Properties

Melting point:
269-271°C
storage temp. 
-20°C Freezer
CAS DataBase Reference
191732-72-6(CAS DataBase Reference)

SAFETY

Risk Statements  20/21/22
Safety Statements  36/37
HazardClass  IRRITANT
HS Code  29339900

Lenalidomide price More Price(3)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 14643 Lenalidomide ≥98% 191732-72-6 100mg $125 2018-11-13 Buy
Cayman Chemical 14643 Lenalidomide ≥98% 191732-72-6 1g $313 2018-11-13 Buy
Cayman Chemical 14643 Lenalidomide ≥98% 191732-72-6 500mg $188 2018-11-13 Buy

Lenalidomide Chemical Properties,Uses,Production

Antitumor Drug

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.
Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide.
In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.
The above information is edited by the Chemicalbook Geqian.

Chemical Properties

Yellow Solid

Uses

Immunomodulatory drug; analog of Thalidomide.

Uses

Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

Uses

Lovastatin content <1% 98%

Uses

A Thalidomide analog known to have immunomodulatory properties

Definition

ChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.

brand name

Revlimid(Celgene).

Lenalidomide Preparation Products And Raw materials

Raw materials

Preparation Products


Lenalidomide Suppliers

Global( 298)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 sales@frappschem.com China 887 50
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19954 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22043 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1530 55
Hebei Jiangkai Trading Co., Ltd
0086-17197824289/17197824028
alice@hbjkai.com CHINA 277 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555
+86-021-57951555 jack.li@time-chemicals.com CHINA 1374 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32651 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2548 55

View Lastest Price from Lenalidomide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-04 Lenalidomide
191732-72-6
US $2500.00 / KG 1KG 99% 100KG career henan chemical co
2018-07-26 4-Amino-3-chlorophenol hydrochloride
191732-72-6
US $100.00 / KG 1KG 98% 100KG career henan chemical co

191732-72-6(Lenalidomide )Related Search:


  • Revlimid
  • Lenalidomide ,98%
  • 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,Lenalidomide
  • LenalidoMide(CC-5013,RevliMid)
  • (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
  • 3-(4-aMino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
  • (3R)-3-(4-aMino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
  • LenalidoMide (RevliMid)
  • LenalidoMide (CC-5013)
  • LenalidoMide-d5
  • 3-(4-AMino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
  • (3S)-3-(4-amino-1-keto-isoindolin-2-yl)piperidine-2,6-quinone
  • (3S)-3-(4-amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione
  • (3S)-3-(4-amino-1-oxo-isoindolin-2-yl)piperidine-2,6-dione
  • (3S)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
  • lenalidomide
  • 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione
  • LenalidomideLenalidomide
  • 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
  • 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Amines
  • Heterocycles
  • Inhibitor
  • CC-5013
  • Inhibitors
  • Molecular Targeted Antineoplastic
  • CC-5013
  • Revlimi
  • Lenalidomide(other anti-cancers)
  • 191732-72-6
  • SGT67 lila@tuskwei.com
  • To the amine
  • Lenalidomide (This product is only available in Japan.)
  • 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione
  • pharmaceutical intermediate
Copyright 2017 © ChemicalBook. All rights reserved